tiprankstipranks
Blurbs

Relay Therapeutics (RLAY) Gets a Buy Rating from Goldman Sachs

Goldman Sachs analyst Salveen Richter maintained a Buy rating on Relay Therapeutics (RLAYResearch Report) today and set a price target of $42.00. The company’s shares closed last Tuesday at $16.81, close to its 52-week low of $14.37.

According to TipRanks.com, Richter is a 5-star analyst with an average return of 30.6% and a 52.2% success rate. Richter covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Vertex Pharmaceuticals, and Crispr Therapeutics AG.

Relay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $42.25, which is a 143.0% upside from current levels. In a report issued on May 9, Berenberg Bank also maintained a Buy rating on the stock with a $45.00 price target.

See the top stocks recommended by analysts >>

Relay Therapeutics’ market cap is currently $1.91B and has a P/E ratio of -4.45.

Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RLAY in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Relay Therapeutics Inc is a precision medicines company focused on enhancing small molecule therapeutic discovery in targeted oncology. Its pipeline products include RLY-1971 and RLY-4008 and among others.

Read More on RLAY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More